No Data
Laika Pharmaceuticals-B (02105) signed a clinical cooperation agreement with eli lilly and co.
Laika Pharmaceuticals-B (02105) announced that the group has reached an agreement with eli lilly and co (NYSE: LLY...
[Special VIP] Deng Shengxing: Market lacks focus, the overall market is sluggish.
King Wo Finance | The Hang Seng Index closed at 19,705 on Wednesday (20th), up 41 points or 0.2%. The market turnover was 114.6 billion yuan. The National Index rose 0.12%, closing at 7,090, and the Technology Index rose 0.41%, reporting 4,413. Innovent Bio (01801) had its target price raised by ubs group, soaring 8.1% for the day; Lai Kai Pharmaceutical (02105) and eli lilly and co are collaborating on clinical trials for obesity treatment, soaring 48.3% for the day; Bitcoin hit a new high yesterday, with related stock Meitu (01357) rising 10.4%; The Dow Jones Index closed at 43,408 points on Wednesday (20th), up 139 points or 0.32%.
Lai Kai Pharmaceutical (2105.HK) is collaborating with eli lilly and co in the USA to conduct clinical research on the treatment of obesity with the new ActRIIA monoclonal antibody LAE102.
This collaboration will accelerate the global development of LAE102. LAE102 is a novel activin receptor type 2A (ActRIIA) antagonistic monoclonal antibody (mAb) designed for weight loss and muscle maintenance in obese patients. On November 20, 2024, lakai pharmaceutical (2105.HK, a global biomedical technology company focused on the development of new drugs for metabolism and oncology) announced a clinical collaboration with eli lilly and co. This collaboration aims to accelerate lakai pharmaceutical's novel ActRIIA monoclonal antibody LAE102 in the field of obesity treatment.
Citic Securities Acting as Placing Agent for Laekna
Laekna to Use Placement Proceeds for R&D
Laekna Seeks to Raise HK$235.62M via Share Placement
No Data
No Data